CN106267003A - A kind of stilbene art anticancer traditional Chinese medicinal composition - Google Patents
A kind of stilbene art anticancer traditional Chinese medicinal composition Download PDFInfo
- Publication number
- CN106267003A CN106267003A CN201610843303.9A CN201610843303A CN106267003A CN 106267003 A CN106267003 A CN 106267003A CN 201610843303 A CN201610843303 A CN 201610843303A CN 106267003 A CN106267003 A CN 106267003A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- chinese medicinal
- radix
- medicinal composition
- anticancer traditional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 title claims abstract description 43
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 43
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 235000021286 stilbenes Nutrition 0.000 title claims abstract description 43
- 239000003814 drug Substances 0.000 claims abstract description 53
- 239000004615 ingredient Substances 0.000 claims abstract description 27
- 229940079593 drug Drugs 0.000 claims abstract description 26
- 239000009636 Huang Qi Substances 0.000 claims abstract description 21
- 210000003038 endothelium Anatomy 0.000 claims abstract description 19
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 18
- 210000000582 semen Anatomy 0.000 claims abstract description 17
- 239000007788 liquid Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 238000002386 leaching Methods 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 4
- 238000013459 approach Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 27
- 210000000952 spleen Anatomy 0.000 abstract description 19
- 231100000614 poison Toxicity 0.000 abstract description 8
- 239000002671 adjuvant Substances 0.000 abstract description 7
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract description 7
- 239000003440 toxic substance Substances 0.000 abstract description 7
- 230000036039 immunity Effects 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 abstract 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 abstract 1
- 239000004037 angiogenesis inhibitor Substances 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 32
- 206010028980 Neoplasm Diseases 0.000 description 21
- 239000008280 blood Substances 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 19
- 210000004185 liver Anatomy 0.000 description 18
- 230000007812 deficiency Effects 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 13
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 230000017531 blood circulation Effects 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 7
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 6
- 206010061309 Neoplasm progression Diseases 0.000 description 6
- 230000000118 anti-neoplastic effect Effects 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical group C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 5
- 208000019425 cirrhosis of liver Diseases 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 206010025482 malaise Diseases 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 208000019255 Menstrual disease Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 2
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000271039 Agkistrodon Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 240000009138 Curcuma zedoaria Species 0.000 description 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 1
- QRMPRVXWPCLVNI-UHFFFAOYSA-N Curcumenol Natural products C1C(=C)C2CCC(C)C22CC(C(C)C)C1(O)O2 QRMPRVXWPCLVNI-UHFFFAOYSA-N 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 241000124463 Paeonia sterniana Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 244000178320 Vaccaria pyramidata Species 0.000 description 1
- 235000010587 Vaccaria pyramidata Nutrition 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002115 aflatoxin B1 Substances 0.000 description 1
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 1
- 229930020125 aflatoxin-B1 Natural products 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000010109 chemoembolization Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 1
- ISFMXVMWEWLJGJ-NZBPQXDJSA-N curcumenol Chemical compound CC1=C[C@](O2)(O)C(=C(C)C)C[C@@]22[C@@H](C)CC[C@H]21 ISFMXVMWEWLJGJ-NZBPQXDJSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004345 fruit ripening Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000001363 mesenteric artery superior Anatomy 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000019509 white turmeric Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000008945 zhigancao decoction Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a kind of stilbene art anticancer traditional Chinese medicinal composition, this stilbene art anticancer traditional Chinese medicinal composition is made up of the acceptable adjuvant of effective ingredient and medical science, and described effective ingredient is made up of the crude drug of following quality proportioning: the Radix Astragali 10～50g, Rhizoma Atractylodis Macrocephalae (parched) 15～40g, Radix Bupleuri 5～15g, the Radix Paeoniae Alba 10～20g, Semen Coicis 15～30g, Rhizoma dioscoreae 15～30g, Endothelium Corneum Gigeriae Galli 10～20g, Rhizoma Curcumae 5～20g, Herba Hedyotidis Diffusae 10～30g, Radix Glycyrrhizae Preparata 5～10g.The stilbene art anticancer traditional Chinese medicinal composition of the present invention has effect of invigorating the spleen and benefiting QI and eliminating toxic substances to remove stasis, can effectively suppress HCC hyperplasia, angiogenesis inhibitor, adjust immunity of organism tolerance status, effectively control the development of HCC, shift and recur, improve the quality of life of HCC patient.
Description
[technical field]
The present invention relates to technical field of Chinese medicines, particularly to a kind of stilbene art anticancer traditional Chinese medicinal composition.
[background technology]
Chinese medicine is thought, liver is organ of general, and the five elements belong to wood, has catharsis function.Mechanism of qi, harmonizing emotions can be dredged, promote
Enter bile secretion and excretion with auxiliary taste digestion, endocrine regulation function etc..Forming an integral part with gallbladder for liver, includes few sun and comes into being it
The property of gas, most hair growth promoting.Edema with the liver involved is born in kidney water, is longer than spleen soil, grows the fire of heart monarch.Whole body is protected with free flow of qi mechanism of qi.
Therefore Liver belonging to Yin in physique and Yang in function, interior soft and firm outward, body has the duty resisted foreign aggression and pacified the interior, and pushes up outward the heresy taking advantage of insult, the numerous and disorderly battle in interior town.Therefore liver can be dispelled
Exopathogen is with clean six internal organs, the settling five organs except interior heresy.Visible, liver is the most important defensive barrier of human body.Liver function is normal, human body
Can not only resist exopathogen, and can dispel interior heresy, body secures good health whereby.If liver function is neglected one's duty, then body
Domestic trouble and foreign invasion, can cause multiple disease.The experimental results shows the most both at home and abroad: liver function exception and diabetes, generation
Thank to the disease that many serious threat human lifes such as syndrome, cardiovascular and cerebrovascular disease, hyperlipemia, even malignant tumor etc. are healthy
Closely related.
Hepatocarcinoma (HCC) is one of malignant tumor that world's incidence rate is the highest, in recent years, along with molecular genetics and point
Day by day going deep into of sub-epidemiological study, the pathological research of hepatocarcinoma is achieved with remarkable progress.HCC is the weight jeopardizing human health
Big problem, is the cause of death of the third-largest common cancer.Chronic HBV infection is Asia and African country HCC generation
Major Risk Factors, and in western countries and Japan, chronic hcv infection is Major Risk Factors, has 80%
HCC is to develop on liver cirrhosis basis.It is ordinary person that chronic hepatitis B virus carriers develops into the relative risk of HCC
100 times, the annual loading of liver cirrhosis patient genesis of HCC is about 2-6%.Taking in of aflatoxin B1 increases HCC's further
Ill danger.The whole world about 1.7 hundred million chronic hcv infection person, the most about 20-30% will be developed to liver cirrhosis.
It is 3-5% that liver cirrhosis, HCC annual morbidity once occur.HCC sickness rate is higher with male's sickness rate in the world, men and women
Ratio about 4:1～8:1.In China, the HCC sickness rate of coastal area is higher than interior ground and the northwestward, especially with Qidong, Jiangsu and Guangxi
The sickness rate of two places, Fusui is the highest.The sickness rate of primary hepatocarcinoma raises with advancing age, but at present the sending out of hepatocarcinoma
There is the trend of rejuvenation at the sick age.
HCC treatment at present has occurred that the biggest change, the most several years ago, is diagnosed as during patient HCC not having safety
That benefit treatment with reliable, and their later also total absence of justice.Now, the main research of this complex disease of HCC takes
Obtained progress at full speed, including clinical monitoring and the early diagnosis of HCC, the clinic of HCC and molecular biology classification, and this evil
New development in terms of property ideas of cancer therapy, particularly, the basis of Chinese medicine prevention HCC and clinical research, Chinese herb decoction are controlled
The effective application treated, makes all stages of this disease all may obtain effective treatment.
HCC belongs to the category such as " accumulation ", " carninomatosis " in Chinese medicine, and Chinese medicine thinks that tumor is due to healthy energy not
Foot, visceral dysfunction, the stagnation of QI, blood stasis, expectorant are solidifying, poison is poly-and are formed.The etiology and pathogenesis of hepatocarcinoma in general deficiency in origin and excess in superficiality, with
Insufficiency of the spleen is this, and the stagnation of QI, blood stasis, heresy damp and hot, malicious are mark.Chinese medicine determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs is method with invigorating the spleen and benefiting QI, dispersing liver and promoting blood circulation removing toxic substances, can carry
High immunity of organism and antitumaous effect, control propagation and the transfer of cancerous cell；Chinese medicine can reduce the pair of chemicotherapy and operation simultaneously
Effect, additionally Chinese medicine and western medicine combined radio chemotherapy, play Chinese and western drugs each strong point, can effectively prevent or alleviate chemotherapy bad instead
Should, it is ensured that patient can smoothly complete chemotherapeutic treatment, can increase tumor cell to the sensitivity of chemotherapeutics, improve body to chemotherapy
Tolerance, improve the quality of living and extend life cycle.The main pathogenesis of hepatocarcinoma is blood stasis due to qi deficiency, qi depression to blood stasis, dampness-heat in the liver and gallbladder
And deficiency and exhaustion of liver-YIN, proportion is followed successively by 80.9%, 10.6%, 6.4% and 2.1%.
Problem about cirrhosis, liver precancerous lesion is clinical popular at present, and Explore multi-disciplinary combines suppression hepatic precancerosis
Therapeutic Method, can raising curative effect by a relatively large margin.Chinese medicine has raising immunity of organism and antitumaous effect, hepatocarcinoma initial stage, control with
Soothing the liver, invigorate blood circulation, method that dampness removing, removing toxic substances and removing food stagnancy etc. take stopgap measures is main, middle and late stage first strengthening the body resistance, method with invigorating the spleen and benefiting QI, support
Blood easing the affected liver and enriching yin and nourishing kidney are main, and determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs embodies Chinese medicine individualized treatment characteristic, to because of, verification treatment, obtain relatively
Good curative effect.Additionally Chinese medicine combined chemotherapy, play Chinese and western drugs respective strong point, can effectively prevent or alleviate chemotherapy bad instead
Should, it is ensured that sufferer can smoothly complete chemotherapeutic treatment, can increase tumor cell to the sensitivity of chemotherapeutics, improve body to chemotherapy
Tolerance, improve the quality of living and extend life cycle etc., Chinese medicine has antitumaous effect simultaneously, can strengthen chemotherapeutic efficacy.
[summary of the invention]
It is an object of the invention to provide a kind of stilbene art anticancer traditional Chinese medicinal composition, this stilbene art anticancer traditional Chinese medicinal composition can have
The propagation of effect suppression hepatocarcinoma, Antineoplastic angiogenesis, control cancer cell metastasis, delay tumour progression, improve HCC patient raw
Bioplasm amount.
Technical scheme is as follows:
A kind of stilbene art anticancer traditional Chinese medicinal composition, described stilbene art anticancer traditional Chinese medicinal composition is acceptable with medical science by effective ingredient
Adjuvant forms, and described effective ingredient is made up of the crude drug of following quality proportioning:
The Radix Astragali 10～50g, Rhizoma Atractylodis Macrocephalae (parched) 15～40g, Radix Bupleuri 5～15g, the Radix Paeoniae Alba 10～20g, Semen Coicis 15～30g, Rhizoma dioscoreae
15～30g, Endothelium Corneum Gigeriae Galli 10～20g, Rhizoma Curcumae 5～20g, Herba Hedyotidis Diffusae 10～30g, Radix Glycyrrhizae Preparata 5～10g.
In order to obtain more preferable effect, the described effective ingredient of the present invention can also be preferably by the raw material of following quality proportioning
Medicine is made:
The Radix Astragali 15～40g, Rhizoma Atractylodis Macrocephalae (parched) 20～35g, Radix Bupleuri 10～15g, the Radix Paeoniae Alba 10～15g, Semen Coicis 15～25g, Rhizomadioscoreae
Medicine 15～25g, Endothelium Corneum Gigeriae Galli 10～20g, Rhizoma Curcumae 5～15g, Herba Hedyotidis Diffusae 10～25g, Radix Glycyrrhizae Preparata 5～10g.
In order to obtain more preferable effect, the described effective ingredient of the present invention can also be preferably by the raw material of following quality proportioning
Medicine is made:
Radix Astragali 10g, Rhizoma Atractylodis Macrocephalae (parched) 15g, Radix Bupleuri 5g, Radix Paeoniae Alba 10g, Semen Coicis 15g, Rhizoma dioscoreae 15g, Endothelium Corneum Gigeriae Galli 10g, Rhizoma Curcumae
5g, Herba Hedyotidis Diffusae 10g, Radix Glycyrrhizae Preparata 5g.
In order to obtain more preferable effect, the described effective ingredient of the present invention can also be preferably by the raw material of following quality proportioning
Medicine is made:
Radix Astragali 50g, Rhizoma Atractylodis Macrocephalae (parched) 40g, Radix Bupleuri 15g, Radix Paeoniae Alba 20g, Semen Coicis 30g, Rhizoma dioscoreae 30g, Endothelium Corneum Gigeriae Galli 20g, Rhizoma Curcumae
20g, Herba Hedyotidis Diffusae 30g, Radix Glycyrrhizae Preparata 10g.
In order to obtain more preferable effect, the described effective ingredient of the present invention can also be preferably by the raw material of following quality proportioning
Medicine is made:
Radix Astragali 30g, Rhizoma Atractylodis Macrocephalae (parched) 20g, Radix Bupleuri 10g, Radix Paeoniae Alba 15g, Semen Coicis 20g, Rhizoma dioscoreae 25g, Endothelium Corneum Gigeriae Galli 15g, Rhizoma Curcumae
15g, Herba Hedyotidis Diffusae 20g, Radix Glycyrrhizae Preparata 8g.
The described stilbene art anticancer traditional Chinese medicinal composition of the present invention is oral agents, such as granule, capsule or tablet.
Stilbene art anticancer traditional Chinese medicinal composition of the present invention can use various common preparation method to obtain, one of which
Simple and easy to do preparation method comprises the following steps:
1), by proportioning weighting raw materials, put it in marmite, add the dipped powder of clear water 2～3cm, and soak 10～
15min；
2), first with high heat the described crude drug being immersed in marmite clear water is boiled, change into afterwards slow fire boiling 20～
30min, after leaching decocting liquid, standby；
3), by step 2) filter remaining filtering residue successively according to step 1) and step 2) operational approach, carry out again
Process, cross leaching decocting liquid, standby；
4), will be in step 2) and step 3) in the decocting liquid mixing that obtains concentrate, and stir, form Chinese medicine composition molten
Liquid formulation.
Preferably, in described step 1) in, clear water dipped powder 3cm.
Preferably, in described step 1) in, soak time is 15min.
Preferably, in described step 2) in, the slow fire boiling time is 20min.
The theoretical foundation of the present invention is:
The Radix Astragali, has another name called continuous stilbene, for herbaceos perennial, its have enhancing human body immunity function, protect the liver, diuresis, defying age,
Anti-stress, blood pressure lowering and wide antibacterial action.It is mainly used in, in the gas of spleen reinforcing lung, improving body immunity.
Rhizoma Atractylodis Macrocephalae (parched), the Rhizoma Atractylodis Macrocephalae is the dry rhizome of the feverfew Rhizoma Atractylodis Macrocephalae, Rhizoma Atractylodis Macrocephalae (parched) have invigorating the spleen and benefiting QI, dampness diuretic, hidroschesis,
Antiabortive effect, cures mainly insufficiency of the spleen lack of appetite, abdominal distention is had loose bowels, phlegm retention vertigo and palpitation, edema, spontaneous perspiration and frequent fetal movement.
Radix Bupleuri: meridian distribution of property and flavor, bitter, it is slightly cold.Return liver, gallbladder meridian.There is effect of reconciling superficies and interior, depressed liver-energy dispersing and QI regulating and yang invigorating.With
In cold, fever, alternate attack of chill and fever, distending pain in the chest and hypochondrium, menoxenia, sub-official prolapses, proctoptosis.1, for alternate attack of chill and fever, cold, fever etc.
Disease.Treatment is evil in few sun, alternate attack of chill and fever, is often equal to use with Radix Scutellariae, the Rhizoma Pinelliae；Cure cold heating, with Radix Puerariae, Gypsum Fibrosum, Radix Scutellariae compatibility.
2, for depression of liver-QI, the pain over the hypochondriac region, menoxenia etc..With the medicine such as Radix Angelicae Sinensis, the Radix Paeoniae Alba, Rhizoma Cyperi, Radix Curcumae with using.3, under the deficiency of vital energy
The diseases such as sunken, chronic diarrhea proctoptosis, uterine prolapse.Join Radix Codonopsis, the Radix Astragali, Rhizoma Cimicifugae etc..
The Radix Paeoniae Alba, also referred to as Paeonia sterniana Fletcher in Journ., be Ranunculaceae Paeonia plant, and perennial herb or undershrub are born in hillside, mountain valley
Bushes or thick grass in, its root can be used as medicine.There is suppressing the hyperactive liver pain relieving, depressed liver-energy dispersing and QI regulating, nourishing blood for regulating menstruation, effect of astringing YIN to stop sweating.With
In headache dizziness, hypochondriac pain, stomachache, limb pain twin, blood deficiency and yellow complexion, menoxenia, spontaneous perspiration, the symptom such as night sweat.
Semen Coicis, for the dry mature kernal of grass Semen Coicis.Tap plant during fruit maturation in autumn, dry, beat
Lower fruit, then dry, remove shell, yellowish-brown seed coat and impurity, collect kernel.Its sweet in the mouth, light, cool in nature.Return spleen, stomach, lung meridian.
Favourable water penetration is wet, invigorating the spleen to arrest diarrhea, eliminating impediment, evacuation of pus, effect of detoxicating and resolving stagnation of pathogens.For edema, tinea pedis, dysuria, insufficiency of the spleen let out
Rush down, arthralgia chiefly caused by damp pathogen contracture, lung abscess, acute appendicitis；Wart, the symptom such as cancerous protuberance.
Rhizoma dioscoreae, meridian distribution of property and flavor, sweet in the mouth, property is put down.Return spleen, lung, kidney channel.Having spleen reinforcing nourishing the stomach, promote the production of body fluid lung benefiting, and the kidney invigorating is puckery
Essence, effect of heat-clearing and toxic substances removing.Cure mainly insufficiency of the spleen lack of appetite, incessant chronic diarrhea, the deficiency of the lung is breathed with cough, emission due to deficiency of the kidney, leukorrhagia, frequent micturition, deficiency-heat are quenched one's thirst.
Endothelium Corneum Gigeriae Galli, Endothelium Corneum Gigeriae Galli, Chinese medicine name.Dry inner wall of sandbag for Phasianidae animal man chicken.Nature and flavor are sweet, flat.Return spleen, stomach,
Small intestinal, bladder warp.There is invigorating the stomach and promoting digestion, arresting seminal emission, hard masses softening and resolving and effect for the treatment of stranguria fossil.Do not disappear for food stagnation, vomiting
Dysentery, infantile malnutrition, the enuresis, seminal emission, the puckery pain of stranguria caused by urinary stone, gallbladder-distention hypochondriac pain.
Rhizoma Curcumae, for the rhizome of zingiberaceous plant Rhizoma Curcumae, Guangxi zedoary and RADIX CURCUMAE.Meridian distribution of property and flavor is pungent, bitter, temperature, returns liver, spleen
Warp.Cure mainly coagulation of QI-blood, trusted subordinate's distending pain, lump in the abdomen, accumulation, dyspepsia do not disappear, women's blood stasis amenorrhea and traumatic injury are had a pain.Cowherb has
Circulation of qi promoting removing blood stasis, blood circulation and removing stasis, removing food stagnancy pain relieving, there is antitumor action.
Herba Hedyotidis Diffusae, hangs down loosely draft for annual, its patent medicine bitter in the mouth, light, cold in nature.Primary efficacy is heat-clearing and toxic substances removing, disappears
Eliminating stagnation, diuresis of blood circulation promoting dehumidifying bitterly, outstanding kind treatment all kinds inflammation.In clinical practice, if finding, Herba Hedyotidis Diffusae compatibility obtains
When, multiple disease can be treated.
Radix Glycyrrhizae Preparata, is leguminous plant, and Radix Glycyrrhizae Preparata is the Radix Glycyrrhizae baked with honey, and it is similar round or oval section, surface
Rufous or taupe brown, micro-glossy, tangent plane yellow to buff, cambium ring is obvious, ray irradiation shape.Zhigancao decoction has
Benefiting qi and nourishing yin, activate yang multiple arteries and veins therapeutic efficiency.
In the stilbene art anticancer traditional Chinese medicinal composition of the present invention, the Radix Astragali, the Rhizoma Atractylodis Macrocephalae are monarch drug, can be with invigorating the spleen and benefiting QI；Rhizoma dioscoreae, chicken
Endothelium corneum, Herba Hedyotidis Diffusae, Rhizoma Curcumae are ministerial drug, Rhizoma dioscoreae tonifying speen and tonifying kidney, Endothelium Corneum Gigeriae Galli hard masses softening and resolving, Rhizoma Curcumae blood circulation and removing stasis, Agkistrodon
SHECAO promoting blood circulation and detoxication dampness removing；Radix Bupleuri, the Radix Paeoniae Alba are adjuvant drug, can be with depressed liver-energy dispersing and QI regulating；Radix Glycyrrhizae Preparata is for making coordinating the actions of various ingredients in a prescription, and full side gathers soothing the liver altogether
Spleen invigorating, the effect of blood circulation promoting and blood stasis dispelling removing toxic substances.Modern pharmacology research proves the Radix Astragali total saponins in the Radix Astragali, astragalus polysaccharides, astragaloside
The growth of hepatocarcinoma can be suppressed, increase the hepatoma carcinoma cell sensitivity to chemotherapeutics, it is possible to reduce the side effect of chemotherapeutics；
Rhizoma Atractylodis Macrocephalae volatile oil and Rhizoma Atractylodis polysaccharide in the Rhizoma Atractylodis Macrocephalae have suppression hepatoma cell proliferation and the effect of transfer；Curcumenol in Rhizoma Curcumae and
Volatile oil and stigmasterol in Oleum Curcumae, Herba Hedyotidis Diffusae all have propagation and the promotion apoptotic effect with suppression hepatoma carcinoma cell；
Saikoside d by suppressing the propagation of hepatoma carcinoma cell on the impact of HIF-1 α/COX-2 signal path.The Radix Astragali is joined with Rhizoma Curcumae
5 can suppress tumor, it may be possible to realized by suppression HIF-1 α, VEGF, and the chemotherapy that simultaneously can also strengthen cisplatin is made
With.
The present invention improves the therapeutic effect of Qi deficiency blood stasis type hepatocarcinoma, can observe by following clinical patient
The confirmation of one step.
One, sufferer overview: sufferer selects 64 example Patients with Primary from January, 2015 in January, 2016 in Shenzhen
Hepatopathy section of institute of traditional Chinese medicine of city inpatient.Wherein male patient 48 example, women sufferer 16 example, age 22～70 years old, the mean age
49.7 years old.And all sufferers is before accepting Drug therapy of the present invention, all carried out the Drug therapy of Chinese and western medicine, medication treatment time
All more than 3 months.The state of an illness of above-mentioned sufferer is as follows:
In sufferer, in the liver of 41 example sufferers, tumor is single-shot focus, and 23 example sufferers are many tuberositys or fill the air type, all sufferers
The mean size of diameter of tumor be 7.2cm.Companion's portal vein tumor thrombus person 8 example, Serum AFP rising person 56 example (AFP ＞ 20 μ g/mL).
According to BCLC staging scale, in described sufferer, sufferer 6 example in early days, mid-term sufferer 36 example, late period sufferer 22 example；Liver function Child
A level 42 example, Child B level 22 example.The KPS scoring of all sufferers is all higher than or equal to 60 points.
All conversion are randomly divided into simple hepatic arterial chemoembolization (TACE) group (matched group) 32 example and Fighting cancer club by us
Associating TACE group (treatment group) 32 examples.Two groups of sufferer clinical datas compare, and no significant difference (P ＞ 0.05), having can
Compare property.
Two, sufferer inclusive criteria:
Reference hepatocarcinoma Professional Committee of Chinese Anti-Cancer Association diagnosing cancer of liver standards in 1999 and BCLC staging scale, in conjunction with
CT, MRI, Serum AFP (alpha-fetoprotein) or pathological examination are made a definite diagnosis, and meet primary hepatocarcinoma syndrome of blood stasis due to qi deficiency diagnostic criteria, disease
See that spiritlessness and weakness, deficiency of QI with disinclination to talk, diarrhea with loose stool and deficient pulse are unable etc..
Three, curative effect index:
Short term effect index:
(1) the solid tumor short term effect standard formulated according to WHO, checks CT and measures tumor volume after terminating the course for the treatment of.
Complete incidence graph (CR): focus is wholly absent, continues more than 4 weeks, occurs without new focus；
Part alleviates (PR): focus major diameter summation reduces >=30%, continues more than 4 weeks, occurs without new focus；
Stable (SD): PR/PD；Progress (PD): focus major diameter summation increases > 20% or new focus occurs.Total effective rate
For CR+PR.
(2) observation index: every 14d checks 1 serum alpha-fetoprotein (AFP) level.
(3) clinical syndrome: evaluate " spiritlessness and weakness, poor appetite lack of appetite, distension and fullness in the abdomen, hypochondriac pain, loose stool " after treating 3 months
Etc. syndrome situation, score according to " normal (0 point), slight (1 point), moderate (2 points), severe (3 points) ".
(4) quality of life KPS scoring: evaluate patients ' life quality with KPS marking scales after treating 3 months, after treatment relatively
Increasing >=10 points of persons before treatment is to improve, and reducing by >=10 points of persons after treatment before relatively treatment is to decline, and change 10 points of persons of ＜ are stable.
Late result index:
From treatment, calculate life cycle, monthly follow up a case by regular visits to after patient discharge 1 time, until dead or follow up a case by regular visits to 1 year.
Four, Therapeutic Method:
1, packet situation: 64 selected example sufferer interactivity language answering system IVRS are carried out randomization selection,
It is divided into treatment group and matched group.Treatment group 32 example, wherein male patient 18 example, women sufferer 14 example；The course of disease 10～20 months, flat
Equal 13.6 months；Age 22～70 years old, average 49.7 years old.Matched group 32 example, wherein male patient 20 example, women sufferer 12 example；
The course of disease 10～18 months, average 11.5 months；Age 24～68 years old, average 50.5 years old.Two groups of sufferers are at sex, the course of disease and age
Etc. the clean statistical procedures of aspect, difference there are no significant meaning (P > 0.05), there is comparability.
2, Therapeutic Method:
The sufferer for the treatment of group and matched group all carries out TACE treatment, and operating process is as follows: routine Seldinger method, warp
Skin femoral artery puncture intubates, and at Digital Subtraction (DSA) descending coeliac artery, superior mesenteric artery and phrenicartery radiography, specifies swollen
After the feeding artery of tumor, choose supply artery of the tumor, first by mould with Pingyang for ultra-liquefied lipiodol 10～30mL by super further for conduit
Injected plug after element 8mg+ mitomycin 30mg suspendible, finally with absorbable gelatin sponge particle thromboembolism.After injection, then row DSA makes
Shadow, observes tumor feeding disappearance and completes for operation.Postoperative routine is given hemostasis, antibacterials, emesis and strengthens liver protection treatment.According to
Tumor presence, general row 1～3 TACE treatments, 4 weeks each interval times；This treatment all completes in my institute's interventional therapy room.
The treatment by Chinese herbs for the treatment of group starts after TACE treats on the 2nd day, and sufferer is taken invention formulation and treated, treatment
Group the sufferer daily present invention Chinese medicine composition prepare medicinal liquid, dose is 1 times/day, 1 time 1 bag, often bag 150～
200ml, using 1 month as 1 course for the treatment of, takes 3 courses for the treatment of altogether.Matched group does not take the Chinese medicine composition of the present invention.
Five, interpretation of result:
Treatment group and matched group total effective rate are respectively 90.6% (29/32), 65.6% (21/32), and tumor recurs for the first time
Rate is respectively 9.37% (3/32), 34.38% (11/32), two groups of comparing differences statistically significant (P < 0.05)；Therapeutic alliance
Can effectively reduce serum alpha-fetoprotein level, significantly improve tcm syndrome, statistically significant with matched group comparing difference (P <
0.05)。
Conclusion: the stilbene art anticancer traditional Chinese medicinal composition associating TACE of the present invention treats Qi deficiency blood stasis type hepatocarcinoma sufferer, can
To be obviously improved the life quality of patient, reduce the recurrence of tumor and improve the survival rate of patient.
A kind of stilbene art anticancer traditional Chinese medicinal composition of the present invention, has invigorating the spleen and benefiting QI, soothing the liver removing toxic substances and effect of blood circulation promoting and blood stasis dispelling,
Can effectively suppress the propagation of hepatocarcinoma, Antineoplastic angiogenesis, control cancer cell metastasis, delay tumour progression, improve HCC
Patients ' life quality, the probability curing Qi deficiency blood stasis type hepatocarcinoma is the highest.It addition, the preparation method of the present invention is easy easily
OK.
During clinical observation, do not find that medicine of the present invention has any bad toxic and side effects, show in the present invention
Drug composition is safe and effective.
[detailed description of the invention]
Below in conjunction with embodiment, the present invention will be described in detail.
Embodiment one
A kind of stilbene art anticancer traditional Chinese medicinal composition of the present embodiment, is made up of the acceptable adjuvant of effective ingredient and medical science, its
Described in effective ingredient be made up of the crude drug of following quality proportioning:
Radix Astragali 10g, Rhizoma Atractylodis Macrocephalae (parched) 15g, Radix Bupleuri 5g, Radix Paeoniae Alba 10g, Semen Coicis 15g, Rhizoma dioscoreae 15g, Endothelium Corneum Gigeriae Galli 10g, Rhizoma Curcumae
5g, Herba Hedyotidis Diffusae 10g, Radix Glycyrrhizae Preparata 5g.
Above-mentioned a kind of stilbene art anticancer traditional Chinese medicinal composition, its effective ingredient is prepared by following methods:
1), by proportioning weighting raw materials, put it in marmite, add clear water dipped powder 3cm, and soak 15min；
2), first with high heat the described crude drug being immersed in marmite clear water is boiled, changes slow fire boiling 20min afterwards into,
After leaching decocting liquid, standby；
3), by step 2) filter remaining filtering residue successively according to step 1) and step 2) operational approach, carry out again
Process, cross leaching decocting liquid, standby；
4), will be in step 2) and step 3) in the decocting liquid mixing that obtains concentrate, and stir, form Chinese medicine composition molten
Liquid formulation.
Above-mentioned stilbene art anticancer traditional Chinese medicinal composition can also be made for granule, capsule or tablet.
The stilbene art anticancer traditional Chinese medicinal composition of the present embodiment can effectively suppress the propagation of hepatocarcinoma, and antineoplastic vascular is raw
Become, control cancer cell metastasis, delay tumour progression, improve HCC patients ' life quality, cure the machine of Qi deficiency blood stasis type hepatocarcinoma
Rate is the highest.It addition, the preparation method of the present invention is simple and easy to do.
Embodiment two
A kind of stilbene art anticancer traditional Chinese medicinal composition of the present embodiment, is made up of the acceptable adjuvant of effective ingredient and medical science, its
Described in effective ingredient be made up of the crude drug of following quality proportioning:
Radix Astragali 50g, Rhizoma Atractylodis Macrocephalae (parched) 40g, Radix Bupleuri 15g, Radix Paeoniae Alba 20g, Semen Coicis 30g, Rhizoma dioscoreae 30g, Endothelium Corneum Gigeriae Galli 20g, Rhizoma Curcumae
20g, Herba Hedyotidis Diffusae 30g, Radix Glycyrrhizae Preparata 10g.
The preparation method of above-mentioned a kind of stilbene art anticancer traditional Chinese medicinal composition, the preparation method of its effective ingredient and embodiment one
Identical.
Above-mentioned stilbene art anticancer traditional Chinese medicinal composition can also be made for granule, capsule or tablet.
The stilbene art anticancer traditional Chinese medicinal composition of the present embodiment can effectively suppress the propagation of hepatocarcinoma, and antineoplastic vascular is raw
Become, control cancer cell metastasis, delay tumour progression, improve HCC patients ' life quality, cure the machine of Qi deficiency blood stasis type hepatocarcinoma
Rate is the highest.It addition, the preparation method of the present invention is simple and easy to do.
Embodiment three
A kind of stilbene art anticancer traditional Chinese medicinal composition of the present embodiment, is made up of the acceptable adjuvant of effective ingredient and medical science, its
Described in effective ingredient be made up of the crude drug of following quality proportioning:
Radix Astragali 30g, Rhizoma Atractylodis Macrocephalae (parched) 20g, Radix Bupleuri 10g, Radix Paeoniae Alba 15g, Semen Coicis 20g, Rhizoma dioscoreae 25g, Endothelium Corneum Gigeriae Galli 15g, Rhizoma Curcumae
15g, Herba Hedyotidis Diffusae 20g, Radix Glycyrrhizae Preparata 8g.
The preparation method of above-mentioned a kind of stilbene art anticancer traditional Chinese medicinal composition, the preparation method of its effective ingredient and embodiment one
Identical.
Above-mentioned stilbene art anticancer traditional Chinese medicinal composition can also be made for granule, capsule or tablet.
The stilbene art anticancer traditional Chinese medicinal composition of the present embodiment can effectively suppress the propagation of hepatocarcinoma, and antineoplastic vascular is raw
Become, control cancer cell metastasis, delay tumour progression, improve HCC patients ' life quality, cure the machine of Qi deficiency blood stasis type hepatocarcinoma
Rate is the highest.It addition, the preparation method of the present invention is simple and easy to do.
Embodiment four
A kind of stilbene art anticancer traditional Chinese medicinal composition of the present embodiment, is made up of the acceptable adjuvant of effective ingredient and medical science, its
Described in effective ingredient be made up of the crude drug of following quality proportioning:
Radix Astragali 25g, Rhizoma Atractylodis Macrocephalae (parched) 15g, Radix Bupleuri 12g, Radix Paeoniae Alba 10g, Semen Coicis 15g, Rhizoma dioscoreae 20g, Endothelium Corneum Gigeriae Galli 12g, Rhizoma Curcumae
10g, Herba Hedyotidis Diffusae 20g, Radix Glycyrrhizae Preparata 10g.
The preparation method of above-mentioned a kind of stilbene art anticancer traditional Chinese medicinal composition, the preparation method of its effective ingredient and embodiment one
Identical.
Above-mentioned stilbene art anticancer traditional Chinese medicinal composition can also be made for granule, capsule or tablet.
The stilbene art anticancer traditional Chinese medicinal composition of the present embodiment can effectively suppress the propagation of hepatocarcinoma, and antineoplastic vascular is raw
Become, control cancer cell metastasis, delay tumour progression, improve HCC patients ' life quality, cure the machine of Qi deficiency blood stasis type hepatocarcinoma
Rate is the highest.It addition, the preparation method of the present invention is simple and easy to do.
In sum, the preferred embodiments of the present invention as above, but above preferred embodiment and be not used to limit the present invention, this
The those of ordinary skill in field, without departing from the spirit and scope of the present invention, all can make various change and retouching, as will be respectively joined
Side is strengthened by the ratio in technical scheme or reduction dose, and the curative effect of prepared this Chinese medicine composition is the most unaffected, therefore
Protection scope of the present invention defines in the range of standard with claim.
Claims (10)
1. a stilbene art anticancer traditional Chinese medicinal composition, described stilbene art anticancer traditional Chinese medicinal composition is acceptable auxiliary by effective ingredient and medical science
Material composition, it is characterised in that described effective ingredient is made up of the crude drug of following quality proportioning:
The Radix Astragali 10～50g, Rhizoma Atractylodis Macrocephalae (parched) 15～40g, Radix Bupleuri 5～15g, the Radix Paeoniae Alba 10～20g, Semen Coicis 15～30g, Rhizoma dioscoreae 15～
30g, Endothelium Corneum Gigeriae Galli 10～20g, Rhizoma Curcumae 5～20g, Herba Hedyotidis Diffusae 10～30g, Radix Glycyrrhizae Preparata 5～10g.
Stilbene art anticancer traditional Chinese medicinal composition the most according to claim 1, it is characterised in that described effective ingredient is by following quality
The crude drug of proportioning is made:
The Radix Astragali 15～40g, Rhizoma Atractylodis Macrocephalae (parched) 20～35g, Radix Bupleuri 10～15g, the Radix Paeoniae Alba 10～15g, Semen Coicis 15～25g, Rhizoma dioscoreae 15
～25g, Endothelium Corneum Gigeriae Galli 10～20g, Rhizoma Curcumae 5～15g, Herba Hedyotidis Diffusae 10～25g, Radix Glycyrrhizae Preparata 5～10g.
Stilbene art anticancer traditional Chinese medicinal composition the most according to claim 1, it is characterised in that described effective ingredient is by following quality
The crude drug of proportioning is made:
Radix Astragali 10g, Rhizoma Atractylodis Macrocephalae (parched) 15g, Radix Bupleuri 5g, Radix Paeoniae Alba 10g, Semen Coicis 15g, Rhizoma dioscoreae 15g, Endothelium Corneum Gigeriae Galli 10g, Rhizoma Curcumae 5g, in vain
Serpentis SHECAO 10g, Radix Glycyrrhizae Preparata 5g.
Stilbene art anticancer traditional Chinese medicinal composition the most according to claim 1, it is characterised in that described effective ingredient is by following quality
The crude drug of proportioning is made:
Radix Astragali 50g, Rhizoma Atractylodis Macrocephalae (parched) 40g, Radix Bupleuri 15g, Radix Paeoniae Alba 20g, Semen Coicis 30g, Rhizoma dioscoreae 30g, Endothelium Corneum Gigeriae Galli 20g, Rhizoma Curcumae 20g,
Herba Hedyotidis Diffusae 30g, Radix Glycyrrhizae Preparata 10g.
Stilbene art anticancer traditional Chinese medicinal composition the most according to claim 1, it is characterised in that described effective ingredient is by following quality
The crude drug of proportioning is made:
Radix Astragali 30g, Rhizoma Atractylodis Macrocephalae (parched) 20g, Radix Bupleuri 10g, Radix Paeoniae Alba 15g, Semen Coicis 20g, Rhizoma dioscoreae 25g, Endothelium Corneum Gigeriae Galli 15g, Rhizoma Curcumae 15g,
Herba Hedyotidis Diffusae 20g, Radix Glycyrrhizae Preparata 8g.
Stilbene art anticancer traditional Chinese medicinal composition the most according to claim 1, it is characterised in that described Chinese medicine composition is granule
Agent, capsule or tablet.
7. according to the stilbene art anticancer traditional Chinese medicinal composition described in any one of claim 1-5, it is characterised in that described Chinese medicine composition
Prepared by following methods:
1), by proportioning weighting raw materials, put it in marmite, add the dipped powder of clear water 2～3cm, and soak 10～
15min；
2), first with high heat the described crude drug being immersed in marmite clear water is boiled, changes slow fire boiling 20～30min afterwards into,
After leaching decocting liquid, standby；
3), by step 2) filter remaining filtering residue successively according to step 1) and step 2) operational approach, process again,
Cross leaching decocting liquid, standby；
4), will be in step 2) and step 3) in the decocting liquid mixing that obtains concentrate, and stir, form Chinese medicine composition solution system
Agent.
Stilbene art anticancer traditional Chinese medicinal composition the most according to claim 7, it is characterised in that in described step 1) in, clear water soaks
Cross powder 3cm.
Stilbene art anticancer traditional Chinese medicinal composition the most according to claim 7, it is characterised in that in described step 1) in, during immersion
Between be 15min.
Stilbene art anticancer traditional Chinese medicinal composition the most according to claim 7, it is characterised in that in described step 2) in, slow fire is decocted
The time of boiling is 20min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610843303.9A CN106267003B (en) | 2016-09-22 | 2016-09-22 | A kind of stilbene art anticancer traditional Chinese medicinal composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610843303.9A CN106267003B (en) | 2016-09-22 | 2016-09-22 | A kind of stilbene art anticancer traditional Chinese medicinal composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106267003A true CN106267003A (en) | 2017-01-04 |
| CN106267003B CN106267003B (en) | 2017-12-22 |
Family
ID=57711828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610843303.9A Active CN106267003B (en) | 2016-09-22 | 2016-09-22 | A kind of stilbene art anticancer traditional Chinese medicinal composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106267003B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107029173A (en) * | 2017-01-16 | 2017-08-11 | 广西壮族自治区肿瘤防治研究所 | A kind of pharmaceutical composition for treating primary carcinoma of liver |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103961643A (en) * | 2014-04-28 | 2014-08-06 | 孙沈平 | Linshi body-immunity-strengthening stagnation-removing pill and application thereof |
-
2016
- 2016-09-22 CN CN201610843303.9A patent/CN106267003B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103961643A (en) * | 2014-04-28 | 2014-08-06 | 孙沈平 | Linshi body-immunity-strengthening stagnation-removing pill and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| 侯俐等: "原发性肝癌的辨证论治进展", 《河南中医》 * |
| 刘庆等: "原发性肝癌的中医治法与方药", 《中西医结合学报》 * |
| 张海等: "疏肝健脾法配合介入治疗中晚期肝癌", 《中国中医药信息杂志》 * |
| 高春玲等: "中西医结合治疗中晚期肝癌30例临床观察", 《中国医师杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107029173A (en) * | 2017-01-16 | 2017-08-11 | 广西壮族自治区肿瘤防治研究所 | A kind of pharmaceutical composition for treating primary carcinoma of liver |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106267003B (en) | 2017-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104225441A (en) | Traditional Chinese medicine composition for treating stomach trouble and preparation method of granules and capsules of traditional Chinese medicine composition | |
| CN109010468A (en) | Antitumor Chinese and its preparation method and application based on ancient prescription Tuoli Xiaodu | |
| CN103550696B (en) | Medicine for treating lung cancer | |
| CN105920546A (en) | Soft-liver spleen-shrinking traditional Chinese medicine composition for treating hepatitis B liver cirrhosis | |
| CN108635544A (en) | Treat Hashimoto's thyroiditis Chinese medicine composition and its preparation method and application | |
| CN103463566B (en) | Traditional Chinese medicine composition for treating chronic bronchitis | |
| CN104606580A (en) | Traditional Chinese medicine preparation with synergistic effect on chemotherapy and preparation method of traditional Chinese medicine preparation traditional Chinese medicine preparation | |
| CN106267003B (en) | A kind of stilbene art anticancer traditional Chinese medicinal composition | |
| CN103285343B (en) | Medicine for treating liver cancer and preparation method thereof | |
| CN105233188A (en) | Traditional Chinese medicine composition for treating liver cancer and application of traditional Chinese medicine composition | |
| CN105381424A (en) | Traditional Chinese medicine for detoxifying human viscera and preparation method of traditional Chinese medicine | |
| CN104940418A (en) | Pure traditional Chinese medicine pills for treating hepatitis and preparation method thereof | |
| CN107802774A (en) | Chinese medicine of tonifying spleen lung cough-relieving asthma and preparation method thereof | |
| CN104958537A (en) | Traditional Chinese medicinal composition for treating stomach cancer and preparation method thereof | |
| CN111760006A (en) | Medicine formula for treating liver cirrhosis | |
| CN105902897A (en) | Pharmaceutical preparation for treating pancreatic cancer and application thereof | |
| CN105535839A (en) | Traditional Chinese medicine tablets for treating colon cancer and preparation method thereof | |
| CN104524372A (en) | Traditional Chinese medicine preparation for treating cervical cancer | |
| CN104998074A (en) | Traditional Chinese medicine for treating gastropathy and preparation method thereof | |
| CN104888178A (en) | Infantile diarrhea treatment traditional Chinese medicine | |
| CN104491800A (en) | Traditional Chinese medicine composition for treating chronic colitis | |
| CN102961704A (en) | Pharmaceutical composition for treating liver caner and method for preparing dispersible tablets thereof | |
| CN106074918A (en) | A kind of soothing the liver fat Chinese medicine composition that disappears treating non-alcohol fatty liver | |
| CN106361970A (en) | Traditional Chinese medicine for treating lung cancer | |
| CN108743880A (en) | A kind of Chinese medicine composition for treating hepatocellular carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |